Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis Sells 400 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now owns 22,588 shares of the company’s stock, valued at $1,569,414.24. The trade was a 1.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Edwards Lifesciences Stock Performance

Shares of EW opened at $68.49 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business has a 50-day simple moving average of $72.14 and a two-hundred day simple moving average of $70.37. The stock has a market cap of $40.26 billion, a price-to-earnings ratio of 9.83, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on EW shares. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Truist Financial restated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $79.95.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently made changes to their positions in EW. Leavell Investment Management Inc. grew its position in shares of Edwards Lifesciences by 3.3% during the third quarter. Leavell Investment Management Inc. now owns 9,923 shares of the medical research company’s stock worth $655,000 after purchasing an additional 321 shares in the last quarter. Ownership Capital B.V. grew its position in shares of Edwards Lifesciences by 1.2% during the third quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock worth $197,509,000 after purchasing an additional 34,597 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in shares of Edwards Lifesciences by 3.1% during the third quarter. State of New Jersey Common Pension Fund D now owns 226,465 shares of the medical research company’s stock worth $14,944,000 after purchasing an additional 6,723 shares in the last quarter. Kennebec Savings Bank purchased a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $79,000. Finally, Patten & Patten Inc. TN grew its holdings in Edwards Lifesciences by 7.5% during the 3rd quarter. Patten & Patten Inc. TN now owns 164,904 shares of the medical research company’s stock valued at $10,882,000 after buying an additional 11,512 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.